Amsterdam; The Netherlands / Helsinki; Finland (22nd May, 2021): AMR Insights and The Global Antibiotic Resistance Foundation (TGARF) are happy to announce the global collaboration on combating Antimicrobial resistance (AMR). For professionals in the ‘One Health’ sectors worldwide who wish to prevent Antimicrobial resistance, AMR Insights offers relevant global information, specific education and extensive partnering opportunities. TGARF focuses on increasing the global awareness on AMR, especially related to governmental institutes, media, medical staff, authorities and patient platforms. Both parties are committed to eliminating AMR because they do not accept that millions of innocent people need to die as a result of resistant bacteria and other microorganisms. The parties have signed a Memorandum of Understanding to lay down the intentions to join forces.
Dr Maarten van Dongen, Director AMR Insights, said:
” AMR is a growing global problem. The key to successfully combating AMR is for professional organisations to cooperate and to complement each other wherever possible. Let’s tear down the walls around our organisations instead of building and strengthening them.”
This fits perfectly into TGARF’s strategy:
“By cooperating with the media, we will make governments, doctors, patient organisations much more aware of AMR. We see many opportunities in the global cooperation with AMR Insights.”
according to Stephanie van Rossum, COO of TGARF.
Terkko Health Hub and TGAR Foundation started a cooperation
Terkko Health Hub and TGAR Foundation signed an MOU to create awareness about AMR and the Patient Platform for the Nordic Finnish Student Campus.
MEMORANDUM OF UNDERSTANDING
Helsinki; Finland (29th Nov, 2022): Do Company OY-Terkko Health Hub and The Global Antibiotic Resistance Foundation (TGARF) are proud to have signed an MOU related to their collaboration on combating Antimicrobial resistance (AMR). Terkko Health Hub represents the biggest start-up and innovation environment in a student campus in Finland and can promote specific education which could give extensive partnering opportunities. TGARF focuses on increasing global awareness related to AMR.
AMR is one of the top three underlying causes of death in the world. And we have in Terkko community: start ups, students, doctors and researchers. The best way to tackle this issue is to raise awareness about it in this community. These are the representatives of this matter and are the people who study it, who learn it, who tackle it, especially dentistry and medical students.
-Rashad Ismayil
TGAR FOUNDATION and OAZIS HEALTH collaborating to combat Global Antimicrobial Resistance
Kigali; Rwanda/ Helsinki; Finland (30th of January 2024): Our organizations, THE GLOBAL ANTIBIOTICS RESISTANCE FOUNDATION (TGARF) and OAZIS HEALTH, are proud and happy to announce their collaboration on combating Global Antimicrobial resistance (AMR).
Both organizations will closely work together to empower future healthcare providers (students) and patients to contain the threat of Antimicrobial Resistance.
Containing Antimicrobial Resistance, through capacity building of future and current healthcare providers, students, and patients, is one of the core goals of OAZIS HEALTH and TGARF.
Future healthcare providers need to know more about this global health threat that still receives limited attention in healthcare education, research and policy discussions. Empowering healthcare students on AMR prepares them to become future antimicrobial stewards during their practices and inspires them to pursue thesis and further careers related to AMR like One Health among these. With time, they become policy makers and researchers who advocate and promote antimicrobial saving practices and policies. Patients need to be able to show their face and use their voice in telling their stories about AMR and inform the Public about the coming danger of increasing AMR.
The GAR Foundation and OAZIS Health have started their collaboration to create platforms, among others but not solely, for empowering and informing patients and students about AMR. Some of those platforms will be used for webinars and courses raising AMR awareness.
Healthcare students will be able to acquire more knowledge to prepare them to become our future antimicrobial stewards.
TGARF FOUNDATION has been introduced to be part of B2B2B AMRDx network, with around 70 international research network partners
As antimicrobial resistance (AMR) becomes more widespread, efforts to extend the usability of current antimicrobial agents by developing and applying diagnostics to identify the appropriate narrow-spectrum antimicrobial for each infection take centre stage. However, diagnostic developers currently suffer from late-stage attrition, creating a “valley of death” that prevents diagnostic tools from reaching patients. The B2B2B AMRDx network is a cross-disciplinary, geographically diverse and gender-balanced group of partners from universities (bench), hospitals (bedside), for-profits (business), governments and nonprofits (beyond), with expertise in all One Health settings: human, animal, and environmental AMR. Improved communications between stakeholders in multiple sectors, an objective of the WHO’s Oslo Medicines Initiative, benefits the development of rapid, reliable AMR diagnostics. We focus on 3 objectives to address the challenges faced by AMR diagnostics developers. Objective 1 expands an open, self-curated, comprehensive online AMR Diagnostics Developer Directory (ADDD) to facilitate exchange of ideas and create synergies in the field. Objective 2 further develops the JPIAMR Seq4AMR Virtual Benchmarking Platform (VBP) for genotype-to-phenotype microbial benchmarking studies that will include gold standard whole genome sequences, phenotypes, and metadata, as well as accompanying microbial isolates. Objective 3 defines policy Pathways to AMR-specific Incentives for Developing Diagnostics (PAIDD), maximizing public health benefits from the use of AMR diagnostics.
With the growing threat of antimicrobial resistance (AMR) worldwide, and few novel antimicrobials being developed, it is becoming more and more important to quickly, accurately and inexpensively diagnose infections and the precise microbe causing them in order to treat them with the right antimicrobial and prevent the emergence of further resistance. However, the path to developing such diagnostics is full of challenges, so much that the space between developing a working prototype and getting a diagnostic used in patients is often called the “valley of death”. Our network, B2B2B AMRDx, brings together a diverse group of researchers from universities (bench), hospitals (bedside), for-profits (business), governments and nonprofits (beyond), to tackle some of these challenges. We have expertise in human, animal, and environmental AMR, and come from 20 different countries. Our goals are as follows. First, we create a comprehensive online AMR Diagnostics Developer Directory (ADDD) to facilitate exchange of ideas in the field. Second, we extend the JPIAMR Seq4AMR Virtual Benchmarking Platform (VBP) to allow diagnostics developers to systematically evaluate their diagnostics on a collection of high-quality genotypes (genomic data) and phenotypes (antimicrobial resistance data) and identify their strengths and weaknesses. Third, we identify new policy directions that can support diagnostics development and adoption by accounting for the public health benefits of using AMR diagnostics. These developments will help AMR diagnostics cross the “valley of death” and help patients.